AZD-4635

Research use only, not for human use.

AZD-4635 (HTL 1071) is a potent, selective and orally available adenosine 2A receptor (A2AR) inhibitor with Ki of 1.7 nM.

AZD-4635 (HTL 1071) is a potent, selective and orally available adenosine 2A receptor (A2AR) inhibitor with Ki of 1.7 nM, > 30-fold selectivity over other adenosine receptors; reverses the inhibitory effects of different concentrations of adenosine in CHO cells stably expressing human A2AR with IC50 of 0.1 nM (incubated with 0.1 uM adenosine); reverses suppression and restores IFNγ secretion in cells incubated with NECA in ex vivo CD8+ T cell assay; reduces tumor burden and enhances antitumor immunity in vivo.Lung Cancer Phase 2 Clinical(In Vitro):In the presence of 0.1, 1 and 10 μM adenosine, the IC50s of AZD4635 for inhibition of cAMP production are 0.79, 10.0 and 142.9 nM, respectively.

In the presence of 0.1, 1 and 10 μM adenosine, the IC50s of AZD4635 for inhibition of cAMP production are 0.79, 10.0 and 142.9 nM, respectively.

——

HTL 1071

GPCR/G Protein

Adenosine Receptor

A2A

Cancer

Lung Cancer

1321514-06-0

315.736

C15H11ClFN5

>98% (HPLC)

DMSO: Soluble （ < 1 mg/ml refers to the product slightly soluble or insoluble )

NC1=NC(C2=CC=C(F)C=C2)=C(C3=CC(C)=NC(Cl)=C3)N=N1

6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine

(-20℃)

With Ice Pack

≥ 2 years